KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Steris (STE) Research & Development (2018 - 2025)

Steris has reported Research & Development over the past 8 years, most recently at $29.5 million for Q4 2025.

  • For Q4 2025, Research & Development rose 7.66% year-over-year to $29.5 million; the TTM value through Dec 2025 reached $111.7 million, up 3.99%, while the annual FY2025 figure was $107.6 million, 3.83% up from the prior year.
  • Research & Development for Q4 2025 was $29.5 million at Steris, up from $28.2 million in the prior quarter.
  • Over five years, Research & Development peaked at $29.5 million in Q4 2025 and troughed at $17.5 million in Q1 2021.
  • A 5-year average of $24.9 million and a median of $25.4 million in 2022 define the central range for Research & Development.
  • Biggest five-year swings in Research & Development: soared 51.02% in 2021 and later dropped 6.17% in 2023.
  • Year by year, Research & Development stood at $24.8 million in 2021, then increased by 2.78% to $25.5 million in 2022, then decreased by 1.02% to $25.3 million in 2023, then grew by 8.49% to $27.4 million in 2024, then rose by 7.66% to $29.5 million in 2025.
  • Business Quant data shows Research & Development for STE at $29.5 million in Q4 2025, $28.2 million in Q3 2025, and $26.4 million in Q2 2025.